53 results
8-K
EX-99.1
VVOS
Vivos Therapeutics Inc
15 May 24
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
2:54pm
market conditions in OSA and open Vivos up for greater revenue opportunities. By doing this, we expect to position Vivos for long-term, sustainable … lease liability
Other current liabilities
Total current liabilities
Long-term liabilities
Contract liabilities, net of current portion
Employee
8-K
EX-99.1
VVOS
Vivos Therapeutics Inc
28 Mar 24
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
8:38pm
ourselves in a better position for long-term revenue growth. We have made substantial progress and are now starting to see the benefits of our actions … and create long-term revenue opportunities for us.
“Perhaps most important, in November, we received FDA 510(k) clearance for our CARE oral medical
424B1
VVOS
Vivos Therapeutics Inc
1 Dec 23
Prospectus with pricing info
4:12pm
” treatment for over 90% of OSA patients, but no one wants to wear those devices to bed every night for life, rendering long-term compliance rates low … harm our business, financial condition and results of operations.
The long-term success of our VIP program is highly dependent on our ability
8-K
EX-99.1
d8727d8x6b6au4
16 Aug 23
Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update
4:30pm
8-K
EX-99.1
br2p2nrdgntcy
8 Jun 23
Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update
5:00pm
8-K
EX-99.1
9xfywlkrd az
30 Mar 23
Vivos Therapeutics Reports Fourth Quarter and Full Year 2022
5:14pm
8-K
EX-99.1
ozv39ug 0b7m
20 Dec 22
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update
4:15pm
8-K
EX-99.1
qdl55
16 May 22
Vivos Therapeutics Reports First Quarter 2022
4:10pm